The Technical Analyst
Passage Bio Inc [PASG]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Passage Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.17% $1.150
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70.85 mill |
| EPS: | -1.860 |
| P/E: | -0.620 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 61.61 mill |
| Avg Daily Volume: | 0.356 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.620 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.620 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0838 (-107.28%) $-1.234 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.990 - 1.310 ( +/- 13.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Borthwick Kathleen | Buy | 227 000 | Employee Stock Option (right to buy) |
| 2024-03-15 | Forman Mark S | Buy | 203 000 | Employee Stock Option (right to buy) |
| 2024-03-15 | Chou William | Buy | 575 000 | Employee Stock Option (right to buy) |
| 2024-03-15 | Cale Edgar B. | Buy | 203 000 | Employee Stock Option (right to buy) |
| 2024-02-10 | Borthwick Kathleen | Buy | 4 000 | Common Stock |
| INSIDER POWER |
|---|
| 82.41 |
| Last 96 transactions |
| Buy: 8 238 559 | Sell: 441 732 |
Forecast:
16:00 - $1.170
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.170
Forecast 2: 16:00 - $1.170
Forecast 3: 16:00 - $1.170
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.150 (-4.17% ) |
| Volume | 0.284 mill |
| Avg. Vol. | 0.356 mill |
| % of Avg. Vol | 79.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PASG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Latest Press Releases
2024-03-04 07:00:00 - Press Release
Passage Bio Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Recent Business Highlights
Philadelphia, march 04, 2024 (globe newswire) -- passage bio, inc. (nasdaq: pasg), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended december 31, 2023 and provided recent business highlights.
2024-02-27 07:00:00 - Press Release
Passage Bio To Participate In Upcoming investor Conferences
Philadelphia, feb. 27, 2024 (globe newswire) -- passage bio, inc. (nasdaq: pasg), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
2024-01-31 07:30:00 - Press Release
Passage Bio To Present At Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Philadelphia, jan. 31, 2024 (globe newswire) -- passage bio, inc. (nasdaq: pasg), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that william chou, m.d., president and chief executive officer, will participate in a fireside chat at guggenheim healthcare talks 6th annual biotechnology conference on thursday, february 8, 2024 at 10:00 a.m. et.
2023-12-20 07:00:00 - Press Release
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of Pbft02 In Ftd-grn And Updated Strategic Priorities
Philadelphia, dec. 20, 2023 (globe newswire) -- passage bio, inc. (nasdaq: pasg), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced initial safety and biomarker data from three cohort 1 patients in the ongoing global phase 1/2 uplift-d clinical trial evaluating pbft02, an adeno-associated virus (aav)-delivery gene therapy for the treatment of patients with frontotemporal dementia (ftd) with granulin (grn) mutations. ftd is a form of early onset dementia with no approved disease-modifying therapies. additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
2023-11-17 16:30:00 - Press Release
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Philadelphia, nov. 17, 2023 (globe newswire) -- passage bio, inc. (nasdaq: pasg), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (cns) disorders, today announced it has granted an inducement award to a new employee.
Latest News
2024-03-07 13:01:14 - Zacks Investment Research
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-27 07:00:00 - GlobeNewsWire
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
2024-02-01 19:09:57 - InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors.
2024-01-31 07:30:00 - GlobeNewsWire
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET.
2023-12-25 22:14:04 - InvestorPlace
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts.
2023-10-30 07:00:00 - GlobeNewsWire
Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET.
2023-09-25 07:00:00 - GlobeNewsWire
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET.
2023-08-01 07:00:00 - GlobeNewsWire
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in the following upcoming investor conferences:
2023-06-05 07:00:00 - GlobeNewsWire
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 3:20 p.m. PT in Dana Point, CA.
2023-04-17 07:00:00 - GlobeNewsWire
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, and Alex Fotopoulos, chief technical officer, will participate in a virtual fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 3:30 p.m. ET.